BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 27259537)

  • 21. Induction of histiocytic sarcoma in mouse skeletal muscle.
    Liu J; Hettmer S; Milsom MD; Hofmann I; Hua F; Miller C; Bronson RT; Wagers AJ
    PLoS One; 2012; 7(8):e44044. PubMed ID: 22952867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: A case report and review of the literature.
    Branco B; Comont T; Ysebaert L; Picard M; Laurent C; Oberic L
    Eur J Haematol; 2019 Oct; 103(4):444-448. PubMed ID: 31376203
    [No Abstract]   [Full Text] [Related]  

  • 23. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone H3K36I mutation in a metastatic histiocytic tumor of the skull and response to sarcoma chemotherapy.
    Snuderl M; Dolgalev I; Heguy A; Walsh MF; Benayed R; Jungbluth AA; Ladanyi M; Karajannis MA
    Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31645348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-wide analysis of acute leukemia and clonally related histiocytic sarcoma in a series of three pediatric patients.
    Bleeke M; Johann P; Gröbner S; Alten J; Cario G; Schäfer H; Klapper W; Khoury J; Pfister S; Müller I
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28074. PubMed ID: 31737984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma.
    Massoth LR; Hung YP; Ferry JA; Hasserjian RP; Nardi V; Nielsen GP; Sadigh S; Venkataraman V; Selig M; Friedmann AM; Samore W; Killian JK; Milante R; Giessinger J; Foley-Peres K; Marcus C; Severson E; Duncan D; Sivakumar S; Ross JS; Desphande V; Ramkissoon SH; Vergilio JA; Louissaint A; Zukerberg LR; Williams EA
    Oncologist; 2021 Jul; 26(7):e1263-e1272. PubMed ID: 33904632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histiocytic sarcoma arising from thyroid gland with BRAF V600E mutation.
    Ge R; Chang Y; Gan Y; Zhu H; Liu C
    Pathology; 2020 Aug; 52(5):603-605. PubMed ID: 32600657
    [No Abstract]   [Full Text] [Related]  

  • 28. Primary central nervous system histiocytic sarcoma with somatic
    Wang W; Zhang Y; Dong Y; Li S; Qin H
    Clin Neuropathol; 2022; 41(6):253-262. PubMed ID: 35652545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib.
    Idbaih A; Mokhtari K; Emile JF; Galanaud D; Belaid H; de Bernard S; Benameur N; Barlog VC; Psimaras D; Donadieu J; Carpentier C; Martin-Duverneuil N; Haroche J; Feuvret L; Zahr N; Delattre JY; Hoang-Xuan K
    Neurology; 2014 Oct; 83(16):1478-80. PubMed ID: 25209580
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry.
    Jabbar KJ; Luthra R; Patel KP; Singh RR; Goswami R; Aldape KD; Medeiros LJ; Routbort MJ
    Am J Surg Pathol; 2015 Apr; 39(4):454-61. PubMed ID: 25634750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
    Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
    Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent chromosome 1p loss.
    Lazo de la Vega L; Hovelson DH; Cani AK; Liu CJ; McHugh JB; Lucas DR; Thomas DG; Patel RM; Tomlins SA
    Hum Pathol; 2016 Dec; 58():161-170. PubMed ID: 27664537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathological and Molecular Characteristics of Mammary Adenoid Cystic Carcinoma With Adipocytic Differentiation With Emphasis on the Identification of a Novel
    Bae GE; Yoon N; Cho EY; Kim HS; Cho SY
    Anticancer Res; 2019 Jan; 39(1):369-374. PubMed ID: 30591482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression.
    Feng YZ; Shiozawa T; Miyamoto T; Kashima H; Kurai M; Suzuki A; Konishi I
    Clin Cancer Res; 2005 Sep; 11(17):6133-8. PubMed ID: 16144912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.
    Crumley SM; Pepper KL; Phan AT; Olsen RJ; Schwartz MR; Portier BP
    Arch Pathol Lab Med; 2016 Jun; 140(6):529-35. PubMed ID: 26536055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
    Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
    Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
    Egan C; Nicolae A; Lack J; Chung HJ; Skarshaug S; Pham TA; Navarro W; Abdullaev Z; Aguilera NS; Xi L; Pack S; Pittaluga S; Jaffe ES; Raffeld M
    Haematologica; 2020 Apr; 105(4):951-960. PubMed ID: 31439678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs.
    Zavodovskaya R; Liao AT; Jones CL; Yip B; Chien MB; Moore PF; London CA
    Am J Vet Res; 2006 Apr; 67(4):633-41. PubMed ID: 16579756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics.
    Rechsteiner M; von Teichman A; Rüschoff JH; Fankhauser N; Pestalozzi B; Schraml P; Weber A; Wild P; Zimmermann D; Moch H
    J Mol Diagn; 2013 May; 15(3):299-311. PubMed ID: 23531339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
    Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
    Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.